The September 16th, 2021 webinar, “COVID-19 Testing in a Residential University Setting,” provided an orientation of the disruptive Simoa® technology, discussed emerging dynamics of the pandemic, including the effects of the highly contagious Delta variant of the virus, and demonstrated the utility of Simoa-enabled, ultra-sensitive detection of the viral antigen in non-invasively collected samples.

The discussion was led by Quanterix Chairman and Chief Executive Officer Kevin Hrusovsky and featured Dr. John Roback, M.D., Ph.D., Professor of Pathology and Laboratory Medicine, Executive Vice-Chair for Clinical Operations, and Medical Director for Emory Medical Laboratories.

It opened with a presentation from Hrusovsky, who shared a vision for advancing preventative medicine and precision health through early disease detection paradigms enabled by ultra-sensitive biomarker measurements in the disease areas of neurology, oncology, and infectious disease, including COVID-19. Dr. Roback then shared the experience of the Emory team navigating the challenges associated with establishing a rapid, high-throughput, accurate COVID-19 testing program to enable a safe, in-person learning experience for the Emory community. Dr. Roback described the critical role the Simoa SARS-CoV-2 N Protein assay played in the Emory program, which to date has screened more than 120,000 students, staff, and faculty samples at Emory University.

VIEW THE RECORDING